TPX2 and prostate carcinoma: Validation of target gene expression patterns in clinical prostate samples confirmed that AIM1, ERGIC1, and TPX2 mRNA levels were significantly elevated in prostate cancer tissues (n = 33), compared to non-malignant control tissue samples (n = 3).